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Omega-3 Polyunsaturated Fatty Acids
and Cardiovascular Diseases
Carl J. Lavie, MD,* Richard V. Milani, MD,* Mandeep R. Mehra, MD,† Hector O. Ventura, MD*
New Orleans, Louisiana; and Baltimore, Maryland
Omega-3 polyunsaturated fatty acid (-3 PUFA) therapy continues to show great promise in primary and, particu-
larly in secondary prevention of cardiovascular (CV) diseases. The most compelling evidence for CV benefits of
-3 PUFA comes from 4 controlled trials of nearly 40,000 participants randomized to receive eicosapentaenoic
acid (EPA) with or without docosahexaenoic acid (DHA) in studies of patients in primary prevention, after myo-
cardial infarction, and most recently, with heart failure (HF). We discuss the evidence from retrospective epide-
miologic studies and from large randomized controlled trials showing the benefits of -3 PUFA, specifically EPA
and DHA, in primary and secondary CV prevention and provide insight into potential mechanisms of these ob-
served benefits. The target EPA  DHA consumption should be at least 500 mg/day for individuals without un-
derlying overt CV disease and at least 800 to 1,000 mg/day for individuals with known coronary heart disease
and HF. Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA -3 PUFA
that provides maximal cardioprotection in those at risk of CV disease as well in the treatment of atherosclerotic,
arrhythmic, and primary myocardial disorders. (J Am Coll Cardiol 2009;54:585–94) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.084t
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yFish oil is a whale of a story, that not surprisingly
gets bigger with every telling.
—Rogans (1)
ish oil is obtained in the human diet by eating oily fish,
uch as herring, mackerel, salmon, albacore tuna, and
ardines, or by consuming fish oil supplements or cod liver
il. However, fish do not naturally produce these oils, but
btain them through the ocean food chain from the marine
icroorganisms that are the original source of the omega-3
olyunsaturated fatty acids (-3 PUFA) found in fish oils.
umerous prospective and retrospective trials from many
ountries, including the U.S., have shown that moderate
sh oil consumption decreases the risk of major cardiovas-
ular (CV) events, such as myocardial infarction (MI),
udden cardiac death (SCD), coronary heart disease
CHD), atrial fibrillation (AF), and most recently, death in
atients with heart failure (HF) (2–8). Considerable atten-
ion has been directed at the various classes of fatty acids and
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2) (Table 1). Most of the evidence for benefits of the -3
UFA has been obtained for eicosapentaenoic acid (EPA)
nd docosahexaenoic acid (DHA), the long-chain fatty
cids in this family. There is, however, some epidemiolog-
cal support for a benefit from alpha-linolenic acid (ALA),
he plant-based precursor of EPA. The American Heart
ssociation (AHA) has currently endorsed the use of -3
UFA at a dose of approximately 1 g/day of combined
HA and EPA, either in the form of fatty fish or fish oil
upplements (in capsules or liquid form) in patients with
ocumented CHD (9). The health benefits of these long-
hain fatty acids are numerous and remain an active area of
esearch (Table 2).
The purpose of this review is to summarize the current
cientific data on the effects of the long chain -3 PUFA in
he primary and secondary prevention of various CV disor-
ers and to highlight potential directions for CV research
ith these agents.
ackground Epidemiologic Evidence
uring the past 3 decades, numerous epidemiologic and
bservational studies have been published on the CV
enefits of -3 PUFA (2–5). As early as 1944, Sinclair (10)
escribed the rarity of CHD in Greenland Eskimos, who
onsumed a diet high in whale, seal, and fish. More than 30
ears ago, Bang and Dyberg (11–13) reported that despite a
iet low in fruit, vegetables, and complex carbohydrates but
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Omega-3 PUFA and CV Diseases August 11, 2009:585–94high in saturated fat and choles-
terol, serum cholesterol and trig-
lycerides were lower in Greenland
Inuit than in age-matched resi-
dents of Denmark, and the risk of
MI was markedly lower in the
Greenland population compared
with the Danes. These initial ob-
servations raised speculation on
the potential benefits of -3 PUFA
(particularly EPA and DHA) as the
protective “Eskimo factor” (14). Al-
though a detailed review of all
epidemiologic studies is beyond
the scope of this article, data
from Japan, Norway, Holland,
and the U.S. have extended the
seminal work of Bang and Dy-
berg (2,3,14). Recent evidence,
however, has raised the concern
that intrusion of Western dietary
habits, including massive amounts
of shortening and other saturated
fats, into societies such as the
Alaskan Native and Japanese may
partly overwhelm the cardiopro-
tective effects of -3 PUFA (14).
Trials in CHD
Harris et al. (15) have reviewed
25 trials that evaluated the risk of
CHD events as a function of in
vivo levels of -3 PUFA and
showed that reduction in major
V events correlated inversely with the tissue levels of EPA,
nd even more so, with DHA.
Three large randomized trials have documented the
ffects of -3 PUFA in primary and especially in secondary
revention of CHD. In a randomized trial (DART [Diet
nd Reinfarction Trial]) (16) performed 2 decades ago in
,033 men with recent MI, -3 PUFA, either in the form
Abbreviations
and Acronyms
-3 PUFA  omega-3
polyunsaturated fatty acids
AF  atrial fibrillation
AHA  American Heart
Association
ALA  alpha-linolenic acid
CAC  coronary artery
calcification
CHD  coronary heart
disease
CV  cardiovascular
DHA  docosahexaenoic
acid
EPA  eicosapentaenoic
acid
FDA  Food and Drug
Administration
HF  heart failure
ICD  implantable
cardioverter-defibrillator
IMT  intima-media
thickness
LDL  low-density
lipoprotein
LV  left ventricular
MI  myocardial infarction
PPAR  peroxisome
proliferator-activator
receptor
SCD  sudden cardiac
death
Major Classes of Fatty AcidsTable 1 Major Classes of Fatty Acids
Family* Fatty Acids Formula†
I omega-9 Oleic acid C18:1
II omega-6 Linoleic acid C18:2
Arachidonic acid C20:4
III omega-3 -linolenic acid C18:3
EPA C20:5
DHA C22:6
IV saturated fats Palmitic acid C16:0
Stearic acid C18:0
*The omega number refers to the position of the first double bond fro
carbon atoms and total number of double bonds. Adapted with permission fr
DHA  docosahexaenoic acid; EPA  eicosapentaenoic acid.f oily fish or fish oil capsules, reduced 2-year all-cause
ortality by 29% with the benefit almost entirely attribut-
ble to a reduction in CHD mortality. The reduction in CV
vents was particularly impressive in the subgroup who
onsumed fish oil capsules as opposed to simply increasing
ietary fish consumption, likely indicating a threshold effect
f -3 PUFA.
More recently, 2 major randomized control trials were
erformed. The GISSI (Gruppo Italiano per lo Studio della
opravvivenza nell’ Infarto Miocardico)-Prevenzione study
6) randomized 11,323 post-MI patients to -3 PUFA (1
apsule per day providing 850 mg of EPA/DHA in a 1.2:1
atio; currently available as Lovaza, GlaxoSmithKline, Re-
earch Triangle Park, North Carolina) versus usual care
6,17,18). At the end of 1 year of follow-up, patients taking
he fish oil supplement had a 15% reduction in the primary
nd point, including 21% and 30% reductions in total and
V mortality, respectively (Fig. 1). Further analyses showed
hat this endpoint reduction was driven by a highly signif-
cant 45% reduction in SCD, which was evident after only
months. In a subgroup analysis from this trial, the
agnitude of reduction in total mortality and from SCD
ncreased with progressive worsening of left ventricular
LV) systolic function (17). Long-term follow-up has
ontinued to show reductions in major clinical events at
.5-year follow-up (18).
Source
Most vegetable oils (canola, olive); animal fats
Many vegetable oils (corn, safflower, soybean)
Poultry, meats
Selected vegetable oil (flaxseed, canola)
Marine oils and fish
Marine oils and fish
Animal and vegetable fats
Butter, palm oil, kernel oil, coconut oil, and animal fats
ethyl end of the molecule. †The notation shows the total number of
otential EPA and DHA EffectsTable 2 Potential EPA and DHA Effects
Antiarrhythmic effects
Improvements in autonomic function
Decreased platelet aggregation
Vasodilation
Decreased blood pressure
Anti-inflammatory effects
Improvements in endothelial function
Plaque stabilization
Reduced atherosclerosis
Reduced free fatty acids and triglycerides
Up-regulated adiponectin synthesis
Reduced collagen deposition
bbreviations as in Table 1.m the m
om Lavie et al. (2).
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August 11, 2009:585–94 Omega-3 PUFA and CV DiseasesIn another trial, the JELIS (Japan EPA Lipid Intervention
tudy) trial (7), 18,645 patients (14,981 in primary prevention
nd 3,664 in secondary prevention) with hypercholesterolemia
70% women) were randomized to statin alone or statin and
ighly purified EPA 1,800 mg/day. At the end of the 5-year
tudy, those randomized to EPA had a 19% reduction in major
V events (Fig. 2). Unlike the GISSI-Prevenzione study,
owever, which included lower doses of EPA but also DHA,
Figure 1 Fish Oil and Post-MI Prognosis
Early benefit of omega-3 polyunsaturated fatty acid (-3 PUFA) therapy on total mo
mortality. Probability measurements represent relative risk (95% confidence interva
Figure 2 EPA in Primary Prevention
Eicosapentaenoic acid (EPA) (1.8 g/day) reduced the incidence of major
adverse coronary events in the JELIS (Japan EPA Lipid Intervention Study) trial
by 19%. Reprinted, with permission, from Yokoyama et al. (7). CI  confidence
interval.the moderate dose of EPA alone in the JELIS trial was not
ssociated with a reduction in SCD (possibly because of the
irtual absence of SCD in this cohort).
In combination, the DART, GISSI-Prevenzione, and
ELIS trials indicated that -3 PUFA lower CV risk in
oth primary and secondary prevention settings. However,
t should be noted that other studies have not shown
avorable results. For example, a trial by Burr et al. (19)
uggested that patients with angina treated with fish oil
apsules seem to have a higher risk of SCD than untreated
ontrol subjects. Von Schacky and Harris (20) criticized this
rial as being suboptimally conducted or reported, thus the
esults are questionable. Also, a Norwegian study by Nilsen
t al. (21) did not show a benefit of -3 PUFA supplemen-
ation in post-MI patients. Why treatment with -3 PUFA
as successful in Japan but not in Norway, both populations
ith a high background intake of -3 PUFA, is not clear,
ut the much higher number in the former (n  18,645)
ersus the latter (n  300) was likely a factor. Finally, a
ecent trial (the OMEGA trial) was presented that assessed
-3 PUFA (460 mg EPA  380 mg DHA per day) for 1
ear in 3,851 patients 3 to 14 days after acute MI from 104
enters in Germany (22). In these vigorously treated pa-
ients (85% to 95% usage of aspirin, clopidogrel, statins,
eta-blockers, and angiotensin-converting enzyme inhibi-
ors), the arrhythmic event rate and total mortality were only
.7% and 3.7%, respectively, in the placebo group, and this
sudden death, coronary heart disease (CHD) mortality, and cardiovascular
printed, with permission, from Marchioli et al. (18). MI  myocardial infarction.rtality,
l). Rerial showed no benefit of EPA/DHA on any of the primary
o
u
t
r
p
t
a
o
a
o
h
l
s
(
p
p
p
i
E
S
J
t
t
a
e
d
S
2
l
t
t
a
c
b
N
l
t
s
m
(
g
f
e
J
E
W
e
n
c
e
t
C
i
v
U
s
r
i
E
m
r
v
b
a
t
Q
P
a
s
m
r
l
A
u
r
t
b
t
d
i
(
a
s
p
m
g
m
f
I
t
c
o
t
P
w
b

c
s
s
S
e
e
f
588 Lavie et al. JACC Vol. 54, No. 7, 2009
Omega-3 PUFA and CV Diseases August 11, 2009:585–94r secondary end points. Although this study was probably
nderpowered to adequately determine the effects of this
herapy in secondary CHD prevention, these preliminary
esults certainly raise the possibility that -3 PUFA may not
rovide additional short-term protection to low-risk pa-
ients receiving extensive modern post-MI therapies.
This review does not focus on ALA, which is found in
bundance in flaxseed and to a lesser extent in canola and
live oil, walnuts, and other tree nuts, as well as trace
mounts in green leafy vegetables. As the only dietary source
f -3 PUFA, ALA is considered to be inadequate because
umans convert typically 5% of ALA to EPA and even
ess to DHA (23). In some (but not all) epidemiologic
tudies, ALA has been inversely associated with CV events
3,24). For example, in a recent study from a Costa Rican
opulation, ALA intake and blood levels predicted a better
rognosis, independent of fish and EPA/DHA levels, in a
ost-MI population (25). Nevertheless, the overall evidence
s much weaker for ALA than for EPA and DHA.
vidence of Benefit in Atherosclerosis
everal epidemiologic and necropsy studies have indicated that
apanese men have significantly lower levels of atherosclerosis
han Caucasian men residing in the U.S. (26,27). In studies
hat assessed intima-media thickness (IMT) and coronary
rtery calcification (CAC), both independent predictors of CV
vents, Japanese men have lower grades of atherosclerosis than
o the Caucasians residing in the U.S. (26). Recently,
eikikawa et al. (27) have considered the “Japanese factor” in
81 Japanese men born and living in Japan, 281 Japanese men
iving in the U.S., and 360 Caucasian men born and living in
he U.S. The overall results suggested that Japanese men had
he lowest level of atherosclerosis, whereas Japanese in the U.S.
nd Caucasians had similar levels. The-3 PUFA serum levels
orrelated inversely with IMT in the Japanese men, but CAC
urden was not related to -3 PUFA status in any cohort.
evertheless, the differences between carotid IMT and CAC
evels in the 3 groups, which persisted after adjustment for the
raditional CHD risk factors, disappeared after adjustments for
erum -3 PUFA content, suggesting that very high intake of
arine-derived -3 PUFA has antiatherosclerotic effects
14,27). Despite these promising results, other evidence sug-
ests that a very high intake of shortening and other saturated
ats in the Westernized diet may overwhelm the beneficial
ffects of high -3 PUFA intake in Alaskan Natives and the
apanese (14).
vidence in Arrhythmias
e (28) and others (29) have reviewed the antiarrhythmic
ffects of -3 PUFA. Chronic imbalance of the autonomic
ervous system, with increases in symptomatic and/or de-
reases in parasympathetic tone, increases the risk of major CV
vents and dysrhythmias (3,28). Several randomized controlled
rials show that -3 PUFA improve sympathovagal balance.
hristenen et al. (30) found that patients post-MI and with nmpaired systolic function had improvements in heart rate
ariability after 4.3 g/day of EPA and DHA for 12 weeks.
sing lower doses of -3 PUFA, O’Keefe et al. (31) showed
ignificant reductions in resting heart rate, 1-min heart rate
ecovery after exercise, and improvement in heart rate variabil-
ty after 4 months of modest-dose -3 PUFA (810 mg/day
PA and DHA). Geelen et al. (32) showed that 14 weeks of
oderate-dose -3 PUFA (1,260 mg/day EPA and DHA)
educed the average heart rate in patients with complex
entricular arrhythmias. A large study of 5,096 men and women
y Mozaffarian et al. (33) showed that high dietary fish intake was
ssociated with lower heart rate, slower atrial ventricular conduc-
ion, and a substantially lower likelihood of having a prolonged
T interval. In aggregate, these studies suggest that -3
UFA have benefits in improving autonomic function.
Current research suggests that -3 PUFA may prevent fatal
rrhythmias via their ability to inhibit fast, voltage-dependent
odium channels and L-type calcium channels (28). Further-
ore, DHA has been shown to directly inhibit the delayed-
ectifier potassium channel, which is responsible for the depo-
arization phase of ventricular and atrial cardiac potentials.
lthough the relative effects of DHA and EPA remain
ncertain, DHA’s effect on atrial and ventricular repolarization
aises the possibility that DHA could provide greater protec-
ion against dysrhythmias, a fact that is supported by the
eneficial effects of combined EPA and DHA against SCD in
he GISSI-Prevenzione trial (6) but not noted with higher
oses of EPA alone in the JELIS trial (7).
Although -3 PUFA seem to be effective in reducing SCD
n post-MI and in CHD patients with LV dysfunction
6,15–17), 3 trials using -3 PUFA in patients with implant-
ble cardioverter-defibrillators (ICDs) have shown mixed re-
ults (34–36). The initial trial received substantial negative
ublicity when a subgroup of -3 PUFA–treated patients had
ore frequent ICD discharges compared with the placebo
roup, suggesting that these supplements may be proarrhyth-
ic in certain patients (34). In another trial, Leaf et al. (35)
ound a trend for lower risk for the combined end point of
CD discharge death from any cause (28%; p 0.057) in
he group randomized to -3 PUFA, with risk reduction of
lose to 40% (p  0.03) when adjusting for probable episodes
f malignant arrhythmias and compliance. A third trial (and
he largest) showed no significant differences between -3
UFA and placebo in patients with ICD, but in a subgroup
ith prior MI, the -3 PUFA group had a trend toward
enefit (p 0.09) (36). These trials used 1.8, 2.6, and 0.8 g of
-3 PUFA daily, respectively. The GISSI-HF study, dis-
ussed later, did not show any benefits against SCD with the
ame dose of -3 PUFA used in the GISSI-Prevenzione
tudy, raising the possibility that -3 PUFA may not benefit
CD risk with large populations with significant LV dysfunction.
Perhaps the most significant antiarrhythmic effects, how-
ver, have been noted in studies of AF (28). Mozaffarian
t al. (37) showed a 30% lower risk of AF over a 12-year
ollow-up in patients who consumed high quantities of
onfried fish. However, the Rotterdam study (38) found no
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August 11, 2009:585–94 Omega-3 PUFA and CV Diseasesuch correlation. Two studies in patients undergoing coro-
ary artery bypass grafting have suggested 50% reductions
n the development of post-surgical AF in patients pre-
reated with -3 PUFA with the number needed to treat
eing only 5.5 in one study (39); one of the studies also
howed significant reduction in days hospitalized (39,40).
hether these benefits are caused by antiarrhythmic effects,
enefits on autonomic tone, or even anti-inflammatory
ffects is impossible to determine from these trials. How-
ver, these trials point out the potential benefits of -3
UFA in the current epidemic of AF.
vidence of Benefit in HF
ecently, the potential benefits of -3 PUFA have been
xtended to the prevention and treatment of HF. The Car-
Figure 3 Fish Intake and CHF
Survival free of congestive heart failure (CHF) according to consumption of tuna
or other fish that are high in eicosapentaenoic acid and docosahexaenoic acid.
Reprinted, with permission, from Mozaffarian et al. (41).
Figure 4 Fish Oil and Heart Failure Survival
Kaplan-Meier curves for time to all-cause death (A) and for time to all-cause death
from the GISSI-HF Investigators (8). *Estimates were calculated with a Cox propor
the previous year, previous pacemaker, and aortic stenosis. CI  confidence interiovascular Health Study, involving 4,738 men and women
65 years of age, found an inverse association of baked or
roiled fish intake and incident congestive HF (Fig. 3) (41).
his result was supported by recent data from the ARIC
Atherosclerosis Risk in Community) study, showing an in-
erse relationship between -3 PUFA intake and incident HF
n women (42). A recent study by Yamagishi et al. (43) in a
rospective study of nearly 60,000 Japanese followed up for
early 13 years showed an inverse association between fish and
-3 PUFA consumption and CV mortality, especially for HF.
hese results are particularly striking in a society with a compar-
tively high intake of fish and background -3 PUFA intake.
Confirmatory evidence was recently presented and pub-
ished in the GISSI-HF trial (8), a large, factorial, placebo-
ontrolled trial of nearly 7,000 patients with class II to IV
F who were randomized to 1 g of -3 PUFA (1 highly
oncentrated fish oil capsule, Lovaza, containing 850 to 882
g of EPA  DHA), rosuvastatin (10 mg), both, or dual
lacebo. This large and well-done study showed a statisti-
ally significant benefit of the prescription -3 PUFA (Fig.
), including reduction in total mortality (9%; p  0.05)
nd total mortality or hospitalizations for CV diseases
8%; p  0.01). Although these benefits seem to be only
odest, they translate into 56 patients needing to be treated
or 4 years to avoid 1 death or hospital CV admission.
mportantly, this therapy was safe and well tolerated, and the
mprovements in clinical outcomes were additive to that of
ther well-established HF therapies, including beta-blockers,
ngiotensin-converting enzyme inhibitor/angiotensin receptor
lockers, and aldosterone receptor blockers. Unlike the GISSI-
revenzione trial (6), which used the same dose of concen-
rated prescription -3 PUFA, prevention of SCD did not
eem to explain the benefits of fish oil in HF, nor did HF
ospitalizations account for these benefits.
mission to hospital for cardiovascular reasons (B). Reprinted, with permission,
hazards model, with adjustment for admission to the hospital for heart failure in
 hazard ratio; -3 PUFA  omega-3 polyunsaturated fatty acids.or ad
tional
val; HR
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Omega-3 PUFA and CV Diseases August 11, 2009:585–94Questions remain regarding the mechanisms responsible for
he -3 PUFA effects in HF. In addition to the established
ffects of fish oil therapy, both EPA and DHA are potent
ctivators of peroxisome proliferator-activator receptor
PPAR)-alpha (found in the heart) and PPAR-gamma (44).
lthough fatty acids are classically viewed as an energy sub-
trate in the heart, they are also endogenous ligands for PPARs
nd regulate the expression of genes encoding key proteins
ontrolling myocardial fatty acid uptake and metabolism (45).
tanley et al. (46) have shown that a high-fat diet increases
lasma free fatty acid concentration, activating PPAR-alpha in
he heart and stimulating expression of key mitochondrial
roteins involving fatty acid oxidation. Duda et al. (47)
bserved that dietary -3 PUFA from fish oil (1.6 g EPA
HA) significantly increases serum levels of the cardioprotec-
ive adipokine adiponectin in rats subjected to either sham
reatment or hypertension induced by abdominal aortic band-
ng. Most importantly, the increase in adiponectin corre-
ponded to significant attenuation of LV hypertrophy and
orrelated with decreased LV end-systolic volume. Recent
vidence suggests that ligand activation of PPAR-gamma by
PA and/or DHA up-regulates adiponectin and suppression
f inflammatory cytokines (48–50), which could improve
ardiac structure and function in HF (51,52). Thus, important
ardiac remodeling effects may underlie the observed clinical
enefits of fish oils in HF.
In a small 18-week pilot study of 14 patients with class IIII
o IV HF randomized to 5.1 g/day of EPA and DHA, we
howed marked improvements in inflammatory cytokines (e.g.,
umor necrosis factor alpha and interleukin-1), and percent
ody fat in advanced HF, suggesting that fish oil may be
eneficial in decreasing inflammation and cachexia in advanced
F (53). This suggests a potentially novel therapeutic ap-
roach in the late stages of HF. In addition, our study raises
he issue of the dose needed to obtain maximal clinical benefits
n patients with HF. Both the GISSI-HF study (8) and the
apan epidemiological study (43) likewise raised the possibility
hat pharmacological doses may be needed in patients with
F. Animal studies in cardiac remodeling suggest the need for
igher doses as well. Therefore, further studies are needed
etermining not only the optimal dose of -3 PUFA protec-
ion in different stages of HF but also the underlying mecha-
isms accountable for their benefits. However, at present, we
gree with Fonarow’s (54) assertion that -3 PUFA supple-
entation “should join the short list of evidence-based life-
rolonging therapy for HF.”
vidence for Benefit in Hyperlipidemia
he U.S. Food and Drug Administration (FDA) has approved
n -3 PUFA ethyl ester formulation (Lovaza), at a dosage
f 4 g/day for the treatment of very high triglyceride levels
500 mg/dl) (55–57). It is well established that -3 PUFA
ower plasma triglyceride concentrations (20,58,59). The
echanism for these lipid-lowering effects seems to involve
ctivation of PPARs. Although fatty acids are classically lbserved as an energy substrate, they are also endogenous
igands for PPARs and regulate the expression of genes
ncoding key proteins controlling fatty acid uptake and
etabolism and the formation of very-low-density lipopro-
eins carrying triglycerides in the liver (60,61). Although the
xact transcriptional mechanism by which fish oils improve
ipid levels is not completely understood, -3 PUFA do
educe hepatic synthesis of triglycerides and increase hepatic
atty acid beta-oxidation. The triglyceride-lowering doses of
HA and EPA is 3 to 4 g/day. This dose typically reduces
riglyceride levels by 30% to 40% (59) and has been shown
o reduce severely elevated triglyceride levels (500 mg/dl)
y 45%, along with reductions in non–high-density li-
oprotein cholesterol by 14% with a 9% increase in high-
ensity lipoprotein cholesterol (62). When added to base-
ine statin therapy in patients with triglyceride levels
etween 200 and 499 mg/dl, this dosage of -3 PUFA
owers triglyceride levels by close to 30% (63). Generally,
here are no significant improvements in levels of low-
ensity lipoprotein (LDL) cholesterol with fish oil therapy,
specially in patients with elevated triglyceride levels, who
ften notice increases between 5% and 50% (depending on
he severity of the hypertriglyceridemia and baseline LDL
evels) (62). Interestingly, in the JELIS study, moderate
oses of EPA resulted in 10% reductions in LDL choles-
erol beyond that produced by low-dose statins (7). Never-
heless, even when LDL cholesterol increases with -3
UFA, as it can with fibrates and occasionally with niacin,
-3 PUFA–enriched LDL has been reported to be larger
nd fluffier (pattern A), which is potentially less atherogenic
han the smaller, denser (pattern B) LDL particles (64).
lthough typically more expensive than dietary supple-
ents, the capsular form is a standardized prescription
reparation (Lovaza, 4 g) with FDA-approved safety and
fficacy data and is the most concentrated source of DHA
nd EPA available.
dditional Mechanisms
nd Optimal DHA/EPA Ratios
detailed discussion of all of the potential mechanisms of -3
UFA and CV diseases (summarized in Table 2) is beyond the
cope of this review. It appears that -3 PUFA confer CV
enefits largely through DHA and EPA enrichment of mem-
rane phospholipids (65). In addition to mechanisms discussed
bove, -3 PUFA produces vasodilation, reduces blood pres-
ure (31,66), improves arterial and endothelial function (67),
nd reduces platelet aggregation (68). The antiplatelet, anti-
nflammatory, and triglyceride-lowering effects of -3 PUFA
Fig. 5) (69) require relatively higher doses of DHA and EPA
e.g., 3 to 4 g/day), whereas some of the antiarrhythmic effects,
eduction of SCD, and improvement in HF can be achieved at
ower doses (500 to 1,000 mg/day). Nevertheless, higher doses
ay be even more effective in HF, as discussed previously.
lthough the effects of -3 PUFA on C-reactive proteinevels have been inconsistent (70), these agents have been
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August 11, 2009:585–94 Omega-3 PUFA and CV Diseaseshown to suppress production of pro-inflammatory cyto-
ines such as interleukin-1B, interleukin-6, and tumor
ecrosis factor-alpha (71). When administered to obese
atients, 1.8 g of EPA increased the levels of adiponectin,
hich can reduce inflammation and improve insulin sensi-
ivity (72), in addition to the potential beneficial HF effects
iscussed earlier. Although benefits on the autonomic
ervous system are well established and are reviewed
arlier, studies in patients undergoing heart transplanta-
ion suggest that -3 PUFA can reduce heart rate
ndependently of vagal activation (73), in addition to
educing mean arterial pressure and systemic vascular
esistance by 25% and reducing LV hypertrophy and
mproving diastolic function in heart transplantation
atients with cyclosporine-induced hypertension (66).
The optimal doses and ratios of DHA to EPA are
ifficult to decipher. Both DHA and EPA are present in
ost fish, particularly oily ones, generally in a 2:1 ratio
Table 3) (3,74), whereas fish oils typically have a ratio of
:3 or lower (3). Although feeding pure DHA can raise
PA levels to a small extent (75), the reverse is not true
76). Additionally, DHA is far more abundant than EPA
n the myocardium (68). As reviewed earlier, DHA alone
r in combination with EPA may be more important for
rotection against dysrhythmias and SCD than EPA
lone. Although the beneficial effects on dysrhythmias
eem to occur at lower doses, the relative risk of SCD has
een shown to be related with baseline blood levels of
-3 PUFA (Fig. 6) (3,77) and, as reviewed earlier,
rotection against CHD was also inversely related with
issue levels of EPA and, more so, with DHA levels (15).
Figure 5 Fish Oil Dosing and Cardiovascular Impact
Schema of potential dose responses and time courses for altering clinical events
BP  blood pressure; DHA  docosahexaenoic acid; EPA  eicosapentaenoic acidn addition, other surrogate CV markers (arterial pres-
aure, endothelial relaxation and attenuated vascular relax-
tion, and lipoproteins) may be more improved with high
oses of DHA than with similar doses of EPA (78).
siologic effects of fish or fish oil intake.
rinted, with permission, from Mozaffarian and Rimm (69).
ish Content of EPA and DHATable 3 Fish Content of EPA and DHA
Type
DHA
(g/100 g)
EPA
(g/100 g)
DHA and EPA
(g/100 g)
Ratio
DHA/EPA
Tuna
Bluefin 1.141 0.363 1.504 3.1:1.0
Light, canned in water 0.223 0.047 0.270 4.8:1.0
Albacore, canned in water 0.629 0.233 0.862 2.7:1.0
Salmon
Atlantic, farmed 1.457 0.690 2.147 2.1:1.0
Atlantic, wild 1.429 0.411 1.840 3.5:1.0
Chinook 0.727 1.010 1.737 1.0:1.4
Sockeye 0.700 0.530 1.230 1.3:1.0
Mackerel, Atlantic 0.699 0.504 1.203 1.4:1.0
Herring, Atlantic 1.105 0.909 2.014 1.2:1.0
Trout
Rainbow, farmed 0.820 0.334 1.154 2.5:1.0
Rainbow, wild 0.520 0.468 9.988 1.1:1.0
Halibut 0.374 0.091 0.465 4.1:1.0
Cod 0.154 0.004 0.158 38.5:1.0
Haddock 0.162 0.076 0.238 2.1:1.0
Catfish
Channel, farmed 0.128 0.049 0.177 2.6:1.0
Channel, wild 0.137 0.100 0.237 1.4:1.0
Swordfish 0.681 0.087 0.768 7.8:1.0
Grouper 0.213 0.035 0.248 6.1:1.0
Shrimp 0.144 0.171 0.315 1.0:1.2
ata from the USDA Agricultural Research Service (74) and reprinted, with permission, from Lee etof phy
. Repl. (3).
Abbreviations as in Table 1.
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he most commonly observed adverse effects of -3 PUFA
upplementation are nausea, gastrointestinal upset, and
fishy” burp. Prolonged bleeding times, as noted in Green-
and Eskimos and when feeding “hyper-Eskimo” doses of
-3 PUFA (e.g., over 20 g/day) to normal volunteers,
sually remain in the high end of the normal range (3,10).
hese observations, however, raised concerns that higher
ntakes will increase hemorrhagic complications. However,
arris (79), in a comprehensive review, concluded that
here was no increased risk of clinically significant bleeding
oted with -3 PUFA doses of up to 7 g of combined DHA
nd EPA per day, even when combined with antiplatelet
herapy or warfarin.
One of the major concerns, not about EPA and DHA
er se, but about diets high in oily fish, is the consump-
ion of contaminants, namely methyl mercury. For this
eason, the FDA has advised children and pregnant or
ursing women to specifically avoid those fish with a
otentially high content of mercury, such as swordfish,
ile fish, king mackerel, and shark (80). Nevertheless, a
tudy of nearly 12,000 British women during their
regnancy and beyond found that women who exceeded
he U.S. FDA recommendation for fish intake actually
ad offspring with better cognitive and behavioral devel-
pment than offspring of women who consumed less fish
uring pregnancy (81). A large meta-analysis by Mozaf-
arian and Rimm (82) also showed the favorable risk-to-
enefit ratio (1:400) associated with a high consumption
f fish. Importantly, the most commonly consumed
ietary sources of -3 PUFA, such as salmon, sardines,
rout, oysters, and herring, are quite low in mercury (3).
ecause mercury is water soluble and protein bound, it is
resent in the muscle of the fish but not in the oil.
herefore, fish oil supplements should contain negligible
Figure 6 Omega-3 Blood Levels and SCD
Relative risk of sudden cardiac death (SCD) according to baseline blood levels
of omega-3 fatty acids as percentage of total fatty acids. Data from Albert
et al. (77). Reprinted, with permission, from Lee et al. (3).mounts of mercury (83). decommendations
he current AHA dietary guidelines recommend com-
ined EPA and DHA in a dose of approximately 1,000
g/day in patients with CHD (9). This dose is largely
etermined from the GISSI-Prevenzione study, in which
dose of 850 mg was used. For those individuals without
HD, the AHA recommends 2 oily fish meals per week.
his has been shown to be equivalent to about 500
g/day of combined EPA and DHA, the intake associ-
ted with the lowest risk for CHD death in several U.S.
rospective cohort studies (84). Several other major
rganizations, including the National Cholesterol Edu-
ation Program (85), the World Health Organization
86), the European Society of Cardiology (87), the
nited Kingdom Scientific Advisory Committee in Nu-
rition (88), and the American Diabetes Association (89),
ave all provided guidelines that address increasing
onsumption of fish. Based on the GISSI-HF study
esults, we believe that these recommendations, similar to
HD, should also be extended to patients with HF (e.g.,
pproximately 800 to 1,000 mg of combined EPA/DHA
aily) (8,54). In patients with hypertriglyceridemia, mod-
rate to high doses of -3 PUFA (Lovaza, 4 g/day) is an
DA-approved therapy (55–57,64), and this therapy can
e safely combined with any other lipid therapies (statins,
brates, niacin, and so on). Further studies are needed
hat will determine the optimal dosing in various popu-
ations, especially those with HF, as well as the effects of
arious doses on the primary and secondary reduction of
F and more detailed mechanisms responsible for the
enefits noted. Further studies will be needed to address
he potential benefits of assessing blood levels of -3
UFA to determine its role in dosing adjustments and its
alue in CV protection (90). Finally, studies are needed
o determine the optimal mixture of DHA relative to
PA in various populations, as well as in light of the
ecent OMEGA trial (22), to determine the role of -3
UFA in maximally treated contemporary post-MI pa-
ients or other patients with relatively low-risk CHD.
onclusions
onvincing evidence from extensive research over the past 3
ecades points out the potential beneficial effects of -3
UFA in primary prevention, CHD and post-MI, SCD,
F, atherosclerosis, and AF. Based on the growing evi-
ence for the benefits of fish oils, we agree that this story
epresents a “fish tale with growing credibility.” We also
gree with Rogans’ comment from over 20 years ago that
fish oil is a whale of a story, that not surprisingly gets bigger
ith every telling” (1).
cknowledgment
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uring early drafts of this review.
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